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Jervell and Lange-Nielsen Syndrome: Novel Compound 
Heterozygous Mutations in the KCNQ1 in a Korean Family
The Jervell and Lange-Nielsen syndrome (JLNS) is an autosomal recessive syndrome 
characterized by congenital deafness and cardiac phenotype (QT prolongation, ventricular 
arrhythmias, and sudden death). JLNS has been shown to occur due to homozygous 
mutation in KCNQ1 or KCNE1. There have been a few clinical case reports on JLNS in Korea; 
however, these were not confirmed by a genetic study. We identified compound 
heterozygous mutations in KCNQ1 in a 5-yr-old child with JLNS, who visited the hospital 
due to recurrent syncope and seizures and had congenital sensorineural deafness. His 
electrocardiogram revealed a markedly prolonged corrected QT interval with T wave 
alternans. The sequence analysis of the proband revealed the presence of novel compound 
heterozygous deletion/splicing error mutations (c.828–830 delCTC, p.S277del/c.921G>A, 
p.V307V). Each mutation in KCNQ1 was identified on the maternal and paternal side. With 
β-blocker therapy the patient has remained symptom-free for three and a half years. 
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CASE REPORT
Cardiovascular Disorders
INTRODUCTION
The congenital long QT syndrome (LQTS) is a clinical disorder 
of genetic origin. It is characterized by abnormal QT interval 
prolongation (rate-corrected QT or QTc) and susceptibility to 
sudden death owing to a specific type of polymorphic ventricu-
lar tachycardia, torsade de pointes (1).
  Two forms of inherited LQTS have been described: Romano–
Ward syndrome (RWS), an autosomal dominant inherited dis-
order with prolongation of the QTc without other associated 
noncardiac abnormalities (1), and Jervell and Lange-Nielsen 
syndrome (JLNS), an autosomal recessive disorder with LQTS 
associated with sensorineural deafness (2).
  JLNS usually results from homozygous loss-of-function mu-
tations in either KCNQ1 or KCNE1. Patients with JLNS have a 
more severe cardiac phenotype than those with RWS. Further-
more, JLNS accompanies complete loss of Iks in hair cells and 
endolymph of the inner ear, which result in congenital deafness 
(3). In this report, we describe the first case of genetically con-
firmed JLNS in Korea with compound heterozygous mutations 
in KCNQ1. In addition, one of the mutations is a novel splicing 
one, which has never been reported before.
 
CASE REPORT 
A five-year-old boy visited the hospital due to recurrent synco-
pe on April 17, 2006. The first episode had occurred at the age 
of three. It involved seizure-like movement such as tonic-clonic 
activity, eyeball deviation, and loss of consciousness. Such epi-
sodes happened four times during 16 months. They mostly oc-
curred during walking or exercising, and continued for several 
seconds to several minutes; but cardiac resuscitation had never 
been required. 
  His past medical history revealed that he had undergone co-
chlear transplantation due to congenital sensorineural deafness. 
  The patient showed no abnormality during physical and neu-
rologic examination. There was no abnormality observed in the 
electroencephalogram. His resting 12-lead electrocardiogram 
(ECG) revealed a markedly prolonged QTc interval of 590 ms 
(Fig. 1). His ECG showed a structurally normal heart. A 24-ham-
bulatory ECG showed no ventricular arrhythmia. An exercise 
treadmill test showed a marked QTc prolongation as the test pro-
gressed. It also revealed T wave alternans (Fig. 2). At that time, 
he was not on drugs that could extend the duration of QT. Nor 
did he have any electrolyte imbalance such as hypomagnesemia 
or hypocalcemia. Because the diagnosis of LQTS was established, 
an intracardiac electrophysiologic study was not performed. 
  Clinical manifestations of his family members were unremark-
able. No family members had experienced syncope, palpitation, 
epilepsy, or any episode of cardiac arrest. The patient’s father and 
brother had normal QTc intervals, 434 ms and 404 ms, respec-
tively, but his mother had a prolonged QTc interval of 473 ms.Baek JS, et al.  •  Novel KCNQ1 Mutation with Jervell and Lange-Nielsen Syndrome  
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  Molecular genetic analysis revealed that the patient had com-
pound heterozygous mutations in the KCNQ1 gene. One was       
a previously reported deletional mutation, c.828-830delCTC, 
p.S277del. The other was a novel splicing mutation, c.921G>A, 
p.V307V (Fig. 3). The allele frequency of the novel sequence vari-
ation c.921G>A was 0% in a group of 95 healthy controls. The 
nucleotide c.921G is located at the end of exon 6; therefore, sub-
stitution of G to A was predicted to affect the splicing of mRNA. 
To determine the effect of this novel substitution, we performed 
reverse transcription-polymerase chain reaction and detected 
an abnormally spliced 593-bp mRNA product in which the exon 
6 had been skipped (Fig. 3). The subsequent segregation study 
detected c.828-830delCTC heterozygous mutation in his moth-
er, and c.921G>A in both his father and elder brother (Fig. 4). 
  At the initial visit, he was clinically diagnosed with JNLS. β- 
blocker therapy was initiated with oral propranolol (2 mg/kg/
d). Since then, he has remained symptom-free for three and a 
half years, although he has a persistent QT prolongation (QTc= 
551 ms) as of the most recent ECG. 
DISCUSSION
The cardiac delayed rectifier current (Ik) is one of the major de-
terminants of phase 3 repolarization of the cardiac action po-
Fig. 1. Baseline ECG. It reveals a markedly prolonged corrected QT interval (QTc). 
Fig. 2. Tredmill test shows a marked QTc prolongation and T wave alternas as the 
test progresses.
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Fig. 3. A gene study shows that he 
has compound heterozygous muta­
tions in the KCNQ1 gene: Genomic 
DNA sequencing shows (A) c.828_ 
830delCTC, p.S277del, heterozy­
gote, and (B) c.921G>A, p.V307V, 
heterozygote. (C) The RT­PCR detects 
abnormally spliced mRNA product 
in which the exon 6 had been skip­
ped, (D) and sequencing of RT­PCR 
products confirms exon 6 skipping 
due to the mutation, c.921G>A, 
p.V307V.
M, Molecular marker, NC, normal 
control. 
Fig. 4. The pedigree of presented family. 
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tential. It is composed of three independent components: an 
ultrarapid component, called IKur; a rapid component, IKr; and a 
slow and catecholamine-sensitive component, IKs (4). KCNQ1 
encodes the α-subunit and KCNE1 encodes the β-subunit of 
the channel responsible for the voltage-dependent slowly acti-
vating delayed rectifier potassium channel.  
  Homozygous or compound heterozygous mutation in either 
KCNQ1 or KCNE1 (minK) causes the Jervell and Lange-Nielsen 
autosomal recessive form of the disease (JLN1 and JLN2, respec-
tively), which is characterized by cardiac phenotype (long QT 
interval and susceptibility to ventricular arrhythmia) and sen-
sorineural deafness (5, 6).
  JLNS is a very rare disease, found in less than 1% of all patients 
with LQTS. Moreover, only a few cases with compound hetero-
zygous mutations have been reported (2, 7-9).
  In the present study, we described one Korean family in which 
compound heterozygous mutations in KCNQ1 resulted in JLNS 
in the proband. Our findings are the first in Korea to demonstrate 
that compound heterozygote mutations in KCNQ1 causes JNLS. 
One of two mutant alleles has been associated with LQTS (10) 
while the other was a novel sequence variant resulting in an ab-
normal splicing effect of exon 6. 
  JLNS is the most severe among the major variants of LQTS. 
Most patients with JLNS become symptomatic and they have a 
high risk of life-threatening arrhythmias despite treatment with 
β-blockers (11, 12). Furthermore, JLNS patients suffer from car-
diac events in the early period of their lives (11).
  The high-risk group of patients with JLNS includes those with 
a QTc interval exceeding 550 ms or syncope during early child-
hood (birth to fourth year of life), males less than 20 yr old, and 
those with KCNQ1 mutation (12). The high-risk patients are 
strongly recommended implanted cardiac defibrillator (ICD) 
therapy after the age of five, combined with early medical treat-
ment (12). Although the family members of our JNLS patient 
who have the same disease do not show any symptoms so far, 
they may need specific management including ICD therapy or 
medical treatment to prevent a serious, life-threatening cardiac 
event. Hence, it is important to perform genetic analysis and to 
determine whether they have JNLS mutation.
  In general, heterozygous carriers of the JLNS mutation are 
observed to be asymptomatic or mildly symptomatic. One study 
suggested an explanation for sush an observation that frame-
shift/truncating mutations are responsible for the majority of 
JLNS (13, 14). Frameshift/truncating mutations are unable to 
cause dominant-negative suppression under normal circum-
stances because they cannot co-assemble with wild-type nor-
mal subunits. Therefore, JLNS mutations are milder, and there-
fore, in the heterozygous form, do little harm. In contrast, the 
missense mutation in the KCNQ1 gene, which is most common 
in RWS, can co-assemble with normal subunits, and thereby 
exert a dominant-negative suppression effect.
  Despite limited data, our case also supports the above expla-
nation. The patient’s father and brother with a truncating-like 
mutation have normal QTc interval, while his mother with a mis-
sense mutation has prolonged QTc interval.
  Therefore, JLNS requires complete gene screening of all family 
members even if they have normal QTc intervals. Furthermore, 
the carriers need an individual risk evaluation and careful man-
agement depending on the type of mutation. A carrier with a 
missense mutation should be closely observed.
  In conclusion, JLNS has a worse prognosis than any other 
LQTS genetic groups. The importance of genetic diagnosis has 
recently been highlighted. Our report identified compound het-
erozygote deletion/splicing error mutations (c.828–830 delCTC, 
p.S277del/c.921G>A, p.V307V). To the best of our knowledge, 
this mutation is the first identified as JLNS in the Korean popu-
lation. We also suggest early genetic diagnosis for proper man-
agement and genetic counseling. Functional assays of the novel 
mutation were not performed in our study and should be a sub-
ject for future research.
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